This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107322 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. 177Lu–PSMA-PET extends survival. Nat Rev Clin Oncol 18, 542 (2021). https://doi.org/10.1038/s41571-021-00543-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00543-8
This article is cited by
-
Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study
European Journal of Nuclear Medicine and Molecular Imaging (2024)